R Squared Ltd Makes New Investment in GSK plc (NYSE:GSK)

R Squared Ltd acquired a new stake in GSK plc (NYSE:GSK) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 5,170 shares of the pharmaceutical company’s stock, valued at approximately $175,000.

A number of other institutional investors also recently modified their holdings of the stock. AQR Capital Management LLC increased its stake in GSK by 103.4% in the second quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock valued at $1,015,000 after purchasing an additional 13,403 shares in the last quarter. Creative Planning grew its stake in shares of GSK by 4.8% in the 2nd quarter. Creative Planning now owns 203,246 shares of the pharmaceutical company’s stock valued at $7,825,000 after buying an additional 9,322 shares during the period. NewEdge Advisors LLC increased its position in GSK by 61.9% in the 2nd quarter. NewEdge Advisors LLC now owns 70,048 shares of the pharmaceutical company’s stock valued at $2,697,000 after buying an additional 26,793 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in GSK during the 2nd quarter worth approximately $11,181,000. Finally, Lazari Capital Management Inc. boosted its holdings in GSK by 2.5% in the second quarter. Lazari Capital Management Inc. now owns 19,970 shares of the pharmaceutical company’s stock worth $769,000 after acquiring an additional 486 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK stock opened at $35.06 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a 50-day moving average of $33.98 and a 200-day moving average of $37.75. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a market cap of $72.67 billion, a P/E ratio of 22.77, a P/E/G ratio of 1.31 and a beta of 0.63.

Analyst Ratings Changes

GSK has been the topic of a number of research reports. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.